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Syphilis in Pregnancy and Congenital Syphilis: Why CanWe not
yet Face This Problem?
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The increased occurrence of syphilis during pregnancy, and
its severe repercussions to the fetal environment, has been a
cause for concern among health care professionals. It is hard
to comprehend why congenital syphilis has not yet been
controlled, since its agent, the spirochaete Treponema pal-
lidum, is well known and is highly susceptible to penicillin, a
low cost and easily available drug. When we compare the
control of mother-to-child transmission (MTCT) of HIV with
that of syphilis, it is even harder to understand why we have
such success with the first one and disastrous results with
the second!1
When we evaluate the epidemiology of syphilis in preg-
nancy and in the general adult population, we notice that
there were great expectations to eradicate this disease after
WWII, when penicillin was discovered, and its high efficacy
in controlling Treponema confirmed. There was actually a
reduction in the number of cases in the mid-1950s. Never-
theless, therewas a significant increase starting in the 1960s,
due probably to sexual liberation and the growing use of
illicit drugs. A new reduction in the number of cases occurred
again in the 1970s, due to public health campaigns. In the
1980s, a new growth in the number of cases was detected,
strongly associatedwith the HIVepidemic around the world,
sexual promiscuity and the sexual practices ofmenwho have
sex withmen (MSM). At that time, increasing rateswere also
observed in heterosexual individuals who were associated
with promiscuity, unprotected sexual practices and prosti-
tution. Until today, despite many initiatives to reduce the
number of cases, the infection rate in adults is alarming,
particularly among pregnant women and newborns.2,3
Many public health campaigns launched in Brazil in the
last decades, specifically targeting pregnant women, tried to
control the disease and prevent the infection in newborns. By
the end of the 1980s, a new campaign was launched to
“eradicate congenital syphilis by the year 2000”. This cam-
paign focused on educating pregnant women about the
importance of being tested and treated during prenatal
care. Unfortunately, we arrived to the year 2000 with a
higher occurrence of congenital syphilis. At this point, a
new campaign was created trying to control congenital
syphilis by 2012, since eradicating the disease seemed
unrealistic. Again, the campaign failed to reach its goals
and a higher number of infections was observed.3–5
Why is it so hard to face the congenital syphilis problem in
our country?
Because syphilis can be easily diagnosed and efficient
treatment is available at low cost, potential barriers for the
control of the disease have been studied. The role of health
care workers is one of them. The new campaign from the
Ministry of Health in Brazil is focusing on evaluating the
health professional’s role in caring for pregnant women and
preventing congenital syphilis in newborns.4,5
Recent data on syphilis during pregnancy and congenital
syphilis in our country are alarming. A significant proportion
of women and newborns are infected. Among pregnant
women, there was an increase of 1047% between 2005 and
2013. During this same period, an increase of 135% in
congenital syphilis notifications was observed. These num-
bersmightmean that the notification has improved,which in
fact has happened. Nevertheless, this is not enough to explain
the epidemic number of cases in pregnant women and
newborns.5
Data about syphilis cases around the world show that
more than 12 million cases a year, registered by the World
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Health Organization (WHO), happen in the countries with
lessfinancial and social resources. Theywere associatedwith
90,000 neonatal deaths and to 65,000 premature or lowbirth
weight newborns. The global rates for adverse events varied
from 58 tomore than 80%.6 It is estimated that, in 2008, there
were 1,360,485 cases of syphilis in pregnancy around the
world. Of these, 39%were in Africa, 8% in theAmericas, 44% in
Asia and 1.6% in Europe, and 1,085.637 had prenatal care.
Untreated maternal syphilis resulted in 304,000 fetal and
perinatal deaths, andmore than 216,000 infected children at
risk for early death. The majority (87%) of these adverse
events occurred in women who had prenatal care. In 2000,
the WHO launched a campaign to eliminate syphilis MTCT
with the intention to test and treat more than 90% of the
pregnant women by 2015. Unfortunately, this has not hap-
pened yet.3,6
The repercussions in the infected children’s health can be
severe. Syphilis occurrence during pregnancy can result in
bad adverse effects for the concept , ranging from abortions,
fetal or perinatal deaths, to newborns with diverse disease
sequels that can be manifested up to 2 years of age. It is
important to emphasize that 70% of the infected children
have no symptoms at birth. Therefore, it is extremely impor-
tant to screen and treat women during pregnancy.2,4,7
National guidelines determine screening for the infection
twice during prenatal care: early in the pregnancy and at the
beginning of the third trimester. Women should be tested
again at admission to delivery (or to abortion). This strategy
would identifywomenwho had untreated infections prior to
becoming pregnant and the ones who were infected during
pregnancy, labor or delivery. The adequate identification
would lead to the correct treatment, preventing fetal or
neonatal infection.4
The great majority of the infected pregnant women are in
the latent stage of the disease, when no disease symptoms
are manifested yet. Hence, the importance of screening for
the infection through laboratory exams, serological tests and
rapid test.2,4
Identifying primary chancre of syphilis in pregnant wom-
en is not frequent since most of these lesions happen in the
vagina or cervix and are not usually noticed by the patient.
We must always consider the possibility of the presence of
syphilis in any pregnant womanwhomentions a previous or
recent genital ulcer. The occurrence of a cutaneous rash
found on the palms and soles must always bring up the
possibility of secondary stage of syphilis. Another symptom
characteristic of this secondary stage of the disease is the
presence of flat condyloma with multiple surface papillae
lesions, which can many times be misinterpreted as induced
HPV lesions. The majority of women with diagnosis of
syphilis during prenatal care are in the latent stage of the
disease, which is characterized by reactive serological tests
but no clinicalmanifestations or previous history of infection
or treatment.
A study from 2006, which screened pregnant women for
syphilis in the main cities in Brazil, found that 87% of them
were in the latent stage. The risk for syphilis vertical trans-
mission is high when the disease symptoms are present
(primary and secondary stages), varying from 90 to 100%. In
the latent and tertiary stages, the risk varies from 10 to 30%.
Syphilis presents elevated rates of MTCT, and because Trep-
onema is an agent with high molecular weight, its transmis-
sionwill increase in the latest stages of pregnancy due to the
augmented permeability of placental barrier along the preg-
nancy. Mother-to-child-transmission will be higher in the
clinical manifestation stages of the disease also because the
amount of circulating Treponema is larger than in the other
stages.2,4
The strategies to identify the infection during pregnancy
include laboratory tests since most of the women are
asymptomatic. The blueprint screening diagram includes a
non-treponemal test, which combines venereal disease re-
search laboratory (VDRL) and Rapid Plasma Reagin (RPR) Test
associated with treponemal tests including T Pallidum Hem-
agglutinin Assay (TPHA) or Fluorescent Treponemal Anti-
body Absorption (FTA-ABS). The non-treponemal test has
the advantage of being highly sensitive, and its titers can help
to evaluate the response to the treatment. Nevertheless,
since they are based on the detection of anti-cardiolipin
antibodies, these reactions can have false positive results.
False reactive results occur in less than 2% of the screened
uninfected individuals and they can be considered an excep-
tion to the rule. Another problem with the non-treponemal
test is that false negative results can occur in up to 25% of the
individuals in the latent stages of the disease. Since this
situation is more frequently observed in pregnant women, it
is recommended to screen for serum with non-treponemal
and treponemal tests simultaneously. The treponemal tests
are specific for syphilis and they confirm diagnosis. Never-
theless, even after successful treatment of syphilis, the tests
still react and persist as a serum scar for the infection, and
the patient can have positive results for treponemal tests
forever.2,8
Another recently recommended strategy for syphilis
screening is the so-called reverse algorithm strategy. It
consists in initially having an automated treponemal test,
which facilitates the testing of a large number of cases
simultaneously. This screening uses immune enzymatic
techniques (chemiluminescence immunoassay [CLIA] and
chemiluminescent microparticle immunoassay [CMIA])
with the advantage of lower costs and automatization.
Both present high sensitivity but lower specificity. When
an immune enzymatic test is negative, one can discard
infection, but when it is positive, confirmatory VDRL and
TPHA/FTA-ABS tests are necessary.When the CLIA or CMIA is
positive and VDRL and TPHA are negative, it is a case of false
positive. When CLIA or CMIA is positive and VDRL and TPHA
are positive, the syphilis infection is confirmed. These tests
are recommended when there is well structured and effi-
cient laboratory network.2,4,8
Since 2005, the Ministry of Health in Brazil recommends
screening during prenatal care utilizing rapid test in situa-
tions where difficulties with laboratories network exist, or
when there is an intention to expedite syphilis diagnosis for
pregnant women. These tests have similar technology to the
rapid tests for other infections, such as HIV. They are
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laboratory tests with excellent sensitivity and specificity.
Because they are treponemal tests, when positive, they
confirm the infection and indicate the treatment. They
must be followed by VDRL, though, to evaluate responses
to treatment since, even after treatment, the rapid test will
not become negative, just like all the other treponemal tests
(TPHA or FTA-ABS), which will not get negative after suc-
cessful treatment4.
Syphilis treatment during pregnancy must use penicillin,
since there is no evidence of any other drug that can treat the
fetus intra-uterus adequately. The sooner the treatment
initiates, the better for the fetus. Penicillin initiated after
the 14th week is considered a treatment for a potentially
infected fetus due to the high levels of intrauterine trans-
mission of syphilis. Only first trimester treatment prevents
fetal infection.9,10
The recommended penicillin doses are defined by the
mother’s diagnosis of recent or later stage of infection.When
in the primary or secondary stages of the disease, that is,
when there are clinical signs of the disease, the recom-
mended dosage of penicillin regimen is 2.400.000 UI divided
in two injections, one in each gluteus muscle.9,10
Themajorityof pregnantwomenwill haveno symptoms and
no previous history of treatment or knowledge of the infection.
In this situation, the diagnosis is undetermined latent stage of
infection and the patient should be treated with 7.200.000 UI,
divided in 3 weekly injections of 2.400.000 UI.
The efficacy of penicillin in preventing and treating fetal
infection is high. The most efficient treatment regimens are
not yet established, although the ones in use are known to
have highly successful rates.9,10
Another important point in syphilis treatment, as in any
other sexually transmitted disease, is the adequate approach
to treat the woman’s sexual partner(s). Partners should be
called to the health service to receive orientation, to be
clinically evaluated, to collect serum and to be treated. If
partners do not attend to the convocation, the prescription
for medication should be sent through the pregnant woman,
together with a written convocation from the health service.
Partners, aswell aspatients, need tobescreened forother STDs
and to receive information about syphilis reinfection risks and
ways to prevent it. Because of the cultural and social barriers
associatedwith STDs, activities directed to partners need to be
well structured. Health care workers need to be trained to
learn how to deal with these situations efficiently.2,4
Syphilis diagnosis in a pregnant woman requires adher-
ence to an intensive follow up program, which should focus
on preventing reinfection. Monthly VDRL testing is recom-
mended after treatment, as well as the use of condom.
Pregnant women should be alerted about the risks of any
STD to the fetus, in special, syphilis infection.2,4
Adequate prenatal care should include preventive meas-
ures and treatment to avoid any risk to the fetus. Screening
and treatment for syphilis are two actions that certainly have
an impact in reducing morbidity and mortality rates among
these children. We urgently need to sensitize health care
professionals to routinely screen for syphilis during pregnan-
cy, to correctly interpret the tests, and to treat these patients
and their partners accordingly. If health professionals can be
more aware of their role in preventing syphilis MTCT, and if
they can incorporate adequate actions to their practice, we
will certainly reach the same success we did before with
preventing HIV infection transmission. Syphilis screening and
treatment are way less expensive than those for HIV and
should be available in every health care unit in our country.
What might make an impact in preventing the spread of the
infection is to adequately train thehealth care professionals in
prenatal clinics to be aware of the syphilis problem and to act
on it.
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